Grifols stock: buy or sell?
November 15th, 2019
Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally.
Should I buy Grifols stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Having a trading plan helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with Grifols stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Grifols stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we collected 2 ratings published for GRFS stock in the last 30 days.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-6-27||JPMorgan Chase & Co.||Neutral||Overweight|
Grifols stock analysis
Grifols remained constant a tight 0.18% and closed at $21.69.
Grifols remained steady a tight 0.18% and closed at $21.69. On October/3 GRFS price bounced up over the SMA of 200 days demonstrating to be a significant support for this stock. Since SMA100d and SMA200d crossed up on July, GRFS price slid a -0.91%.
Shares of Grifols closed this week at $21.69 and stepped up a slightly good 0.79%.
Having descending tops is not good news for the long side. Although it's only a warning signal, investors should be on alert during next weeks to identify possible new signals. You should be expectant to Grifols price to not slide under , as this would complicate possible price recovery in the short and mid-term. Since SMA20d and SMA40w crossed up early July, GRFS price climbed $0.02 per share (0.09%). Since price and SMA40w lines crossed up by mid June, GRFS climbed $2.68 (14.10%).
Grifols stock price history
Grifols stock went public on June 2nd, 2011 with a price of $6.551. Since then, GRFS stock surged a 231.10%, with a yearly average of 28.90%. If you had invested right after GRFS's IPO a $1,000 in Grifols stock in 2011, it would worth $2,311.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Grifols stock historical price chart
GRFS stock reached 52-week highs on August at $23.03, and all-time highs 2018-06-13 with a price of 24.47.
Grifols stock price target is $22.50How much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. Currently, only 1 price forecast for Grifols stock was published in the last month:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-6-27||JPMorgan Chase & Co.||Upgrades||$21.00||$22.50||7.1%|
Financials and fundamental analysis
Earnings date and Earnings per ShareAfter posting its last earnings report on April, Grifols . As soon as we get its actual EPS from the earnings report, we will extend this report.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual revenues report draw a beatiful gain of 3.91% to $4,486.72 M USD. When comparing 2018 vs 2017, on the other hand, profit margin (that is, the net income divided by revenues) depreciated a -2.05% to 13.30%.
|2013||$2,740 M||-||$346 M12.6%||-|
|2014||$3,355 M||22.46%||$470 M14.0%||36.09%|
|2015||$3,935 M||17.26%||$532 M13.5%||13.16%|
|2016||$4,050 M||2.93%||$545 M13.5%||2.50%|
|2017||$4,318 M||6.62%||$663 M15.3%||21.49%|
|2018||$4,487 M||3.91%||$597 M13.3%||-9.97%|
Quarterly financial resultsGrifols reported $1,222.81 million in revenues for 2018-Q4, a 6.91% improvement compared to previous quarter. Reported quarter income marked $128.35 million with a profit margin of 10.50%. Profit margin slightly fell a -2.56% compared to previous quarter when profit margin was 13.05%. When comparing sales to same quarter last year, Grifols sales marked a dazzling growth and skyrocketed a 14.51%. Looking back to recent quarterly results, Grifols posted 3 positive quarters in a row.
|2017-Q1||$1,131 M||-||$143 M12.6%||-|
|2017-Q2||$1,292 M||14.20%||$164 M12.7%||15.12%|
|2017-Q3||$1,060 M||-17.95%||$154 M14.5%||-6.37%|
|2017-Q4||$1,068 M||0.74%||$231 M21.6%||50.06%|
|2018-Q1||$1,023 M||-4.20%||$143 M14.0%||-37.90%|
|2018-Q2||$1,097 M||7.24%||$176 M16.0%||22.43%|
|2018-Q3||$1,144 M||4.26%||$149 M13.1%||-14.95%|
|2018-Q4||$1,223 M||6.91%||$128 M10.5%||-14.05%|
Grifols ownershipWhen you are planning to buy shares of a stock, it's always worth to overview its ownership structure.
Grifols shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.00% of all shares.
In case of Grifols stock, 60.84% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for GRFS stock account 0.00%, no big difference from last month.
For a better understanding, the next table shows ownership data compared to other related companies:
|Market cap||$14.8 B||$131.2 B||$41.6 B||$4.5 B||$354.9 B|
|Total shares||684.1 M||594.2 M||510.6 M||38.3 M||2,630.0 M|
|Float shares||1,100.0 M||592.9 M||509.7 M||16.4 M||2,630.0 M|
|- Institutional holdings (%)||60.8%||81.9%||88.2%||47.3%||69.2%|
|- Insider holdings (%)||0.0%||0.2%||0.1%||44.1%||0.1%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, November 15th, 2019|
|Day range||$21.63 - $21.77|
|Average true range||$0.36|
|50d mov avg||$20.74|
|100d mov avg||$21.26|
|200d mov avg||$20.09|
Grifols performanceTo better understand Grifols performance you must becnhmark its gains with other related stocks in same sector or industry. For Grifols, the comparison is made against Amgen, Baxter International, China Biologic Products, , Kimberly-Clark and Mylan.
|CBPOChina Biologic Pr...||18.43%||25.67%||57.15%|